Pharming Sets Aggressive 2026 Revenue Target, Pins Hopes on Joenja Growth and Late-Stage Pipeline
At its 2026 Investor Day, Pharming Group projected revenue forecasts that exceed analyst expectations, driven by its flagship drug Joenja and a series of anticipated clinical trial readouts over the next two years. The biotech firm emphasized a strategy of commercial expansion coupled with disciplined financial management.